PER977

DRUG3 trials

Sponsors

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Conditions

Anticoagulation ReversalHealthy

Phase 1

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

CompletedNCT02206087

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Healthy

Start: 2014-06-30End: 2016-03-31Updated: 2020-05-21

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

CompletedNCT02206100

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Healthy

Start: 2014-04-30End: 2014-08-31Updated: 2020-05-21

Phase 2

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

CompletedNCT02207257

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Anticoagulation Reversal

Start: 2014-03-31End: 2015-11-30Updated: 2020-05-21